Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy

International Journal of Clinical Oncology

Volumn 8, Issue 4, 2003, Pages 200-206

  Sato, Yasufumi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Angiopoietin; Antiangiogenesis; VEGF

Indexed keywords

2 METHOXYESTRADIOL; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; BEVACIZUMAB; CELECOXIB; CILENGITIDE; CYCLOOXYGENASE 2 INHIBITOR; DALTEPARIN; ENZASTAURIN; GEFITINIB; HALOFUGINONE; IMATINIB; INTERLEUKIN 12; ISOFLAVONE DERIVATIVE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MATRIX METALLOPROTEINASE INHIBITOR; MEDIMMUNL; MONOCLONAL ANTIBODY LM 609; PROTEIN KINASE C INHIBITOR; REBIMASTAT; ROFECOXIB; SURAMIN; THALIDOMIDE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CARCINOGENESIS; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; HUMAN; LYMPH NODE METASTASIS; METASTASIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANGIOGENESIS INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0141680285     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-003-0342-8     Document Type: Review

References (58)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
2. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674
3. Lyden D, Hattori K, Dias S, et al. (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201
4. Hill JM, Zalos G, Halcox JP, et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348:593-600
5. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
6. Kawasaki T, Kitsukawa T, Bekku Y, et al. (1999) A requirement for neuropilin-1 in embryonic vessel formation. Development 126:4895-4902
7. Yuan L, Moyon D, Pardanaud L, et al. (2002) Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129:4797-4806
8. Shibuya M (2001) Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26:25-35
9. Davis S, Aldrich TH, Jones PF, et al. (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161-1169
10. Maisonpierre PC, Suri C, Jones PF, et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60
11. Valenzuela DM, Griffiths JA, Rojas J, et al. (1999) Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96:1904-1909
12. Hanahan D (1997) Signaling vascular morphogenesis and maintenance. Science 277:48-50
13. Mandriota SJ, Pepper MS (1998) Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 83:852-859
14. Abe M, Sato Y (2001) cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells. Angiogenesis 4:289-298
15. Sundberg C, Kowanetz M, Brown LF, et al. (2002) Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest 82:387-401
16. Folkman J, D'Amore PA (1996) Blood vessel formation: what is its molecular basis? Cell 87:1153-1155
17. Sato Y (2000) Molecular mechanism of angiogenesis transcription factors and their therapeutic relevance. Pharmacol Ther 87:51-60
18. Iwasaka C, Tanaka K, Abe M, et al. (1996) Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 169:522-531
19. Kanno S, Oda N, Abe M, et al. (2000) Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19:2138-2146
20. Oikawa M, Abe M, Kurosawa H, et al. (2001) Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun 289:39-43
21. Nakano T, Abe M, Tanaka K, et al. (2000) Angiogenesis inhibition by transdominant mutant Ets-1. J Cell Physiol 184:255-262
22. Oda N, Abe M, Sato Y (1999) ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin β3. J Cell Physiol 178:121-132
23. Teruyama K, Abe M, Nakano T, et al. (2001) Neurophilin-1 is a downstream target of transcription factor Ets-1 in human umbilical vein endothelial cells. FEBS Lett 504:1-4
24. Sato Y (2003) The ETS family of transcription factors. In: Hoying JB (ed) Genetics of angiogenesis. BIOS Scientific, Oxford, pp 55-68
25. Huang LE, Gu J, Schau M, et al. (1998) Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95:7987-7992
26. Masson N, Willam C, Maxwell PH, et al. (2001) Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J 20:5197-5206
27. Hon WC, Wilson MI, Harlos K, et al. (2002) Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417:975-978
28. Maxwell PH, Wiesener MS, Chang GW, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275
29. Ravi R, Mookerjee B, Bhujwalla ZM, et al. (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 14:34-44
30. Zundel W, Schindler C, Haas-Kogan D, et al. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14:391-396
31. Dameron KM, Volpert OV, Tainsky MA, et al. (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584
32. Nishimori H, Shiratsuchi T, Urano T, et al. (1997) A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15:2145-2150
33. Yu JL, Rak JW, Coomber BL, et al. (2002) Effect of p53 status on tumor response to antiangiogenic therapy. Science 295:1526-1528
34. Morikawa S, Baluk P, Kaidoh T, et al. (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160:985-1000
35. Tanaka S, Mori M, Sakamoto Y, et al. (1999) Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103:341-345
36. Holash J, Maisonpierre PC, Compton D, et al. (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998
37. Ahmad SA, Liu W, Jung YD, et al. (2001) The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 61:1255-1259
38. Hawighorst T, Skobe M, Streit M, et al. (2002) Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 160:1381-1392
39. Hagemeier HH, Vollmer E, Goerdt S, et al. (1986) A monoclonal antibody reacting with endothelial cells of budding vessels in tumors and inflammatory tissues, and non-reactive with normal adult tissues. Int J Cancer 38:481-488
40. Rettig WJ, Garin-Chesa P, Healey JH, et al. (1992) Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89:10832-10836
41. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1:1623-1634
42. Bredow S, Lewin M, Hofmann B, et al. (2000) Imaging of tumour neovasculature by targeting the TGF-β binding receptor endoglin. Eur J Cancer 36:675-681
43. Fonsatti E, Jekunen AP, Kairemo KJ, et al. (2000) Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 6:2037-2043
44. St Croix B, Rago C, Velculescu V, et al. (2000) Genes expressed in human tumor endothelium. Science 289:1197-1202
45. Carson-Walter EB, Watkins DN, Nanda A, et al. (2001) Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61:6649-6655
46. Alitalo K, Carmeliet P (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1:219-227
47. Mandriota SJ, Jussila L, Jeltsch M, et al. (2001) Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20:672-862
48. Skobe M, Hawighorst T, Jackson DG, et al. (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192-198
49. He Y, Kozaki K, Karpanen T, et al. (2002) Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94:819-825
50. Chen HX, Gore-Langton RE, Cheson BD (2001) Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Huntingt) 15:1017, 1020, 1023-1026
51. Hurwitz H, Fehrenbacher L, Cartwright T, et al. (2003) Bevacizumab (Avastin, a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. ASCO abstract no. 3646
52. Mendel DB, Laird AD, Smolich BD, et al. (2000) Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 15:29-41
53. Wood JM, Bold G, Buchdunger E, et al. (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189
54. Laird AD, Vajkoczy P, Shawver LK, et al. (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160
55. Wedge SR, Ogilvie DJ, Dukes M, et al. (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655
56. Holash J, Davis S, Papadopoulos N, et al. (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393-11398
57. Gingras D, Batist G, Beliveau R (2001) AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Rev Anticancer Ther 1:341-347
58. Falardeau P, Champagne P, Poyet P, et al. (2001) Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28:620-625